Dr. Barre’s research with colleagues at CBU:

  • the application of nutrigenetics and nutrigenomics to the nutraceutical prevention and post-onset management of type 2 diabetes in humans with a view to the reduction of polypharmacy
  • utilising an ammonia lyase to synthesise a potential pharmaceutical and optimising conditions to maximise the yield of product

Dr. Barre’s research with colleagues at other universities:

  • attempting to find the molecular cause(s) of type 2 diabetes
  • researching why Cape Bretoners suffer from among the highest incidence and prevalence of type 2 diabetes in Canada and how to reduce such
  • the impact of dietary pulses on plasma lipid/lipoprotein/apolipoprotein B management
  • glycaemic index impact on low density lipoprotein oxidation management via improvements in plasma antioxidant management in overweight and obese persons as well as in gestational diabetes patients
  • improvements in the clinical management of type 2 diabetes from both pre- and post-onset perspectives in first nations’ populations across Canada.